STAT6 degradation and ubiquitylated TRIML2 are essential for activation of human oncogenic herpesvirus

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• STAT6 signaling pathway dysregulation is implicated in various cancers.
• Human oncogenic herpesvirus lytic replication is vital for viral tumorigenesis.
• The specific role of STAT6 in herpesvirus lytic replication is not well understood.

Purpose of the Study:

• To investigate the role of STAT6 in the lytic replication of Kaposi's sarcoma-associated herpesvirus (KSHV).
• To elucidate the molecular mechanisms by which STAT6 influences KSHV lytic replication.

Main Methods:

• Utilized KSHV as a model system.
• Investigated the interaction between RTA (KSHV lytic replication regulator) and STAT6.
• Analyzed STAT6 ubiquitylation and degradation pathways (proteasome and lysosome).
• Assessed the impact of STAT6 degradation on TRIML2 ubiquitylation, cell survival, and virion production.

Main Results:

• RTA interacts with STAT6 and promotes its K48 and K63-linked ubiquitylation, leading to proteasomal and lysosomal degradation.
• Degradation of STAT6 is associated with increased ubiquitylated TRIML2 (a tumor suppressor).
• This process enhances cell survival and virion production during KSHV lytic activation.
• Similar STAT6 degradation patterns were observed in Epstein-Barr virus, herpes simplex virus 1, and cytomegalovirus lytic activation.

Conclusions:

• STAT6 degradation is a critical event for KSHV lytic activation.
• The findings suggest a novel mechanism linking viral replication, host protein degradation, and tumorigenesis.
• Targeting STAT6 degradation may represent a potential therapeutic strategy for KSHV-associated cancers.